5 Cheap Healthcare Stocks to Buy in 2023
Three of the 943 hedge funds part of Insider Monkey's database had bought Molecular Partners AG (NASDAQ:MOLN)'s shares during Q4 2022.
Crescent Biopharma Inc. (CBIO)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 2,748,763 | $32,600,329 | +99% | 1.1% |
| 2. | Vestal Point Capital Ryan Wilder | 1,500,000 | $17,790,000 | 0.6% | |
| 3. | Opaleye Management James A. Silverman | 1,178,300 | $13,974,638 | 1.84% | |
| 4. | Tang Capital Management Kevin C. Tang | 872,398 | $10,346,640 | +29% | 0.51% |
| 5. | ADAR1 Capital Management Daniel Schneeberger | 606,000 | $7,187,160 | 0.53% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.41 | 1,360,000 | $18,237,600.00 | 2,747,866 | 2025-12-04 | Filing | |
| $0.27 | 115,000 | $30,716.50 | 680,403 | 2024-06-21 | Filing | |
| $0.25 | 190,000 | $48,108.00 | 565,403 | 2024-06-20 | Filing | |
| $0.25 | 17,500 | $4,334.75 | 70,643 | 2024-06-18 | Filing | |
| $1.38 | 30,403 | $41,956.14 | 375,403 | 2023-09-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.19 | 260,873 | $50,009.35 | 6,317,565 | 2024-08-08 | Filing | |
| $0.18 | 61,488 | $11,196.96 | 6,578,438 | 2024-08-07 | Filing | |
| $0.18 | 55,732 | $10,187.81 | 6,639,926 | 2024-08-06 | Filing | |
| $0.19 | 164,523 | $30,996.13 | 6,695,658 | 2024-08-05 | Filing | |
| $0.20 | 286,200 | $57,354.48 | 6,860,181 | 2024-08-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,133,514 | $49,023,476 | 0% | |
| 2. | 2,747,866 | $32,589,691 | 2.48% | |
| 3. | 2,133,576 | $25,304,211 | 1.25% | |
| 4. | 1,677,852 | $19,899,325 | 2.61% | |
| 5. | 557,506 | $6,612,021 | 0% |
News See All
5 Stocks with the Lowest PE Ratio
Catalyst Biosciences, Inc. (NASDAQ:CBIO) is a clinical-stage biotech company. In December, Catalyst Biosciences, Inc.
Timothy P. Lynch's Stonepine Capital Portfolio: Top 10 Healthcare Stocks
In this article, we discuss the top 10 healthcare stock picks of Timothy P. Lynch's Stonepine Capital. If you want to skip our detailed analysis of these stocks, go directly to Timothy P.
Is CBIO A Good Stock To Buy Now?
With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth ...
Hedge Funds Are Getting Crazy About Catalyst Biosciences Inc (CBIO)
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...
Hedge Funds Still Very Bullish On Catalyst Biosciences Inc (CBIO)
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Catalyst Biosciences Inc (CBIO): Hedge Fund Sentiment Unchanged But Bullish
Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios.
13G Filing: Nexthera Capital and Catalyst Biosciences Inc. (CBIO)
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing ...
13G Filing: Sio Capital and Catalyst Biosciences Inc. (CBIO)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing...
13G Filing: Laurence W Lytton and Catalyst Biosciences Inc. (NASDAQ:CBIO)
You can access the original SEC filing by clicking here.
Hedge Fund Resource Center Billionaire Hedge Funds
